21 May 2009
Immunosuppression sparing in patient with severe sepsis post renal transplant
K Kotfïs, M Zukowski, J Biernawska, M Zegan, R Bohatyrewicz, A GreczanAnn Transplant 2009; 14(1): 75-75 :: ID: 880476
Abstract
Background: In patients after a renal transplant, life-long immunosuppression is a part of absolutely required treatment to prevent acute graft rejection. Faced with severe infection or impending sepsis the immunosuppression further complicates treatment, especially in case of sepsis-induced secondary immunosuppression.
Case Report: We present a case of a 57-year old female (with h/o autosomal
dominant polycystic kidney disease, hypertension, secondary diabetes mellitus, end-stage chronic renal disease, post bilateral nephrectomy) who was admitted to ICU 2 months after a renal transplant with severe respiratory failure secondary to pneumonia. She subsequently developed septic shock with neutropenia. Routine microbiological screening showed E.coli ESBL (+) growth, patient was treated according to microbiology sensitivity. The immunosuppressive agents (tacrolimus, corticosteroids) were continued throughout the course of treatment to prevent acute graft rejection, mycophenolate mofetil was discontinued on admission to ICU. Despite multimodal approach (including HVCVVH, drotrecogin alfa infusion) patient died on the 4th day after admission (cardiac arrest, asystole).
Conclusions: Net state of immunosuppression is achieved as a balance between exposure to infectious agents (hospital or community sources) and overall immunosuppression level. This case raises one important issue. A question of the timing and extent of immunosuppression withdrawal: at the
diagnosis of severe infection, when the diagnosis of sepsis is made or when
neutropenia occurs in the course of sepsis?
Keywords: Immunosuppression, Kidney Transplantation
In Press
08 Mar 2024 : Original article
Association of Coronary Calcium Score on Cardiac PET During Pre-Kidney Transplant Assessment with Persisten...Ann Transplant In Press; DOI: 10.12659/AOT.943532
14 Mar 2024 : Original article
Impact of Blood Products Transfusion on Patients in the Immediate Post-Lung Transplant Period: A Cohort StudyAnn Transplant In Press; DOI: 10.12659/AOT.943652
14 Mar 2024 : Case report
Treatment of Cavernous Transformation of Portal Vein Caused by Hepatic Cystic Echinococcosis Using Ex Vivo ...Ann Transplant In Press; DOI: 10.12659/AOT.942358
15 Mar 2024 : Review article
Approaches and Challenges in the Current Management of Cytomegalovirus in Transplant Recipients: Highlighti...Ann Transplant In Press; DOI: 10.12659/AOT.941185
Most Viewed Current Articles
05 Apr 2022 : Original article
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
12 Jan 2022 : Original article
Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...DOI :10.12659/AOT.934738
Ann Transplant 2022; 27:e934738
22 Nov 2022 : Original article
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
15 Mar 2022 : Case report
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860